These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 32002309)

  • 1. ASTX660, an antagonist of cIAP1/2 and XIAP, increases antigen processing machinery and can enhance radiation-induced immunogenic cell death in preclinical models of head and neck cancer.
    Ye W; Gunti S; Allen CT; Hong Y; Clavijo PE; Van Waes C; Schmitt NC
    Oncoimmunology; 2020; 9(1):1710398. PubMed ID: 32002309
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dual Antagonist of cIAP/XIAP ASTX660 Sensitizes HPV
    Xiao R; An Y; Ye W; Derakhshan A; Cheng H; Yang X; Allen C; Chen Z; Schmitt NC; Van Waes C
    Clin Cancer Res; 2019 Nov; 25(21):6463-6474. PubMed ID: 31266830
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The non-peptidomimetic IAP antagonist ASTX660 sensitizes colorectal cancer cells for extrinsic apoptosis.
    Knoll G; Ehrenschwender M
    FEBS Open Bio; 2021 Mar; 11(3):714-723. PubMed ID: 33484626
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antagonist of cIAP1/2 and XIAP enhances anti-tumor immunity when combined with radiation and PD-1 blockade in a syngeneic model of head and neck cancer.
    Xiao R; Allen CT; Tran L; Patel P; Park SJ; Chen Z; Van Waes C; Schmitt NC
    Oncoimmunology; 2018; 7(9):e1471440. PubMed ID: 30393585
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Next-generation hypomethylating agent SGI-110 primes acute myeloid leukemia cells to IAP antagonist by activating extrinsic and intrinsic apoptosis pathways.
    Dittmann J; Haydn T; Metzger P; Ward GA; Boerries M; Vogler M; Fulda S
    Cell Death Differ; 2020 Jun; 27(6):1878-1895. PubMed ID: 31831875
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ASTX660, a Novel Non-peptidomimetic Antagonist of cIAP1/2 and XIAP, Potently Induces TNFα-Dependent Apoptosis in Cancer Cell Lines and Inhibits Tumor Growth.
    Ward GA; Lewis EJ; Ahn JS; Johnson CN; Lyons JF; Martins V; Munck JM; Rich SJ; Smyth T; Thompson NT; Williams PA; Wilsher NE; Wallis NG; Chessari G
    Mol Cancer Ther; 2018 Jul; 17(7):1381-1391. PubMed ID: 29695633
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Positioning of the IAP Antagonist Tolinapant (ASTX660) in Colorectal Cancer.
    Crawford N; Stott KJ; Sessler T; McCann C; McDaid W; Lees A; Latimer C; Fox JP; Munck JM; Smyth T; Shah A; Martins V; Lawler M; Dunne PD; Kerr EM; McDade SS; Coyle VM; Longley DB
    Mol Cancer Ther; 2021 Sep; 20(9):1627-1639. PubMed ID: 34389694
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cisplatin and oxaliplatin induce similar immunogenic changes in preclinical models of head and neck cancer.
    Park SJ; Ye W; Xiao R; Silvin C; Padget M; Hodge JW; Van Waes C; Schmitt NC
    Oral Oncol; 2019 Aug; 95():127-135. PubMed ID: 31345380
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The expanding role of IAP antagonists for the treatment of head and neck cancer.
    Kansal V; Kinney BLC; Uppada S; Saba NF; Stokes WA; Buchwald ZS; Schmitt NC
    Cancer Med; 2023 Jul; 12(13):13958-13965. PubMed ID: 37132167
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LCL161, a SMAC-mimetic, Preferentially Radiosensitizes Human Papillomavirus-negative Head and Neck Squamous Cell Carcinoma.
    Yang L; Kumar B; Shen C; Zhao S; Blakaj D; Li T; Romito M; Teknos TN; Williams TM
    Mol Cancer Ther; 2019 Jun; 18(6):1025-1035. PubMed ID: 31015310
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting EZH2 Enhances Antigen Presentation, Antitumor Immunity, and Circumvents Anti-PD-1 Resistance in Head and Neck Cancer.
    Zhou L; Mudianto T; Ma X; Riley R; Uppaluri R
    Clin Cancer Res; 2020 Jan; 26(1):290-300. PubMed ID: 31562203
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Effect of Xevinapant Combined with Ionizing Radiation on HNSCC and Normal Tissue Cells and the Impact of Xevinapant on Its Targeted Proteins cIAP1 and XIAP.
    Fleischmann J; Hildebrand LS; Kuhlmann L; Fietkau R; Distel LV
    Cells; 2023 Jun; 12(12):. PubMed ID: 37371123
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Loss of interferon-gamma inducibility of the MHC class II antigen processing pathway in head and neck cancer: evidence for post-transcriptional as well as epigenetic regulation.
    Meissner M; Whiteside TL; van Kuik-Romein P; Valesky EM; van den Elsen PJ; Kaufmann R; Seliger B
    Br J Dermatol; 2008 May; 158(5):930-40. PubMed ID: 18284388
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel smac mimetic ASTX660 (Tolinapant) and TNF-α synergistically induce necroptosis in bladder cancer cells in vitro upon apoptosis inhibition.
    Wang L; Hu C; Zhao Y; Hu X
    Biochem Biophys Res Commun; 2022 Apr; 602():8-14. PubMed ID: 35247703
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytotoxic effects of SMAC-mimetic compound LCL161 in head and neck cancer cell lines.
    Brands RC; Herbst F; Hartmann S; Seher A; Linz C; Kübler AC; Müller-Richter UDA
    Clin Oral Investig; 2016 Dec; 20(9):2325-2332. PubMed ID: 26846923
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The radiosensitizing activity of the SMAC-mimetic, Debio 1143, is TNFα-mediated in head and neck squamous cell carcinoma.
    Matzinger O; Viertl D; Tsoutsou P; Kadi L; Rigotti S; Zanna C; Wiedemann N; Vozenin MC; Vuagniaux G; Bourhis J
    Radiother Oncol; 2015 Sep; 116(3):495-503. PubMed ID: 26096848
    [TBL] [Abstract][Full Text] [Related]  

  • 17. cIAP1/2 Antagonism Induces Antigen-Specific T Cell-Dependent Immunity.
    Ventre KS; Roehle K; Bello E; Bhuiyan AM; Biary T; Crowley SJ; Bruck PT; Heckler M; Lenehan PJ; Ali LR; Stump CT; Lippert V; Clancy-Thompson E; Conce Alberto WD; Hoffman MT; Qiang L; Pelletier M; Akin JJ; Dougan M; Dougan SK
    J Immunol; 2023 Apr; 210(7):991-1003. PubMed ID: 36881882
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antagonism of inhibitors of apoptosis proteins reveals a novel, immune response-based therapeutic approach for T-cell lymphoma.
    Ferrari N; Ward G; Gewinner C; Davis MP; Jueliger S; Saini H; Munck J; Smyth T; Ferraldeschi R; Keer H; Lyons J; Sims MJ
    Blood Adv; 2021 Oct; 5(20):4003-4016. PubMed ID: 34474469
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Defects in the human leukocyte antigen class I antigen processing machinery in head and neck squamous cell carcinoma: association with clinical outcome.
    Meissner M; Reichert TE; Kunkel M; Gooding W; Whiteside TL; Ferrone S; Seliger B
    Clin Cancer Res; 2005 Apr; 11(7):2552-60. PubMed ID: 15814633
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radiosensitization of head and neck squamous cell carcinoma by a SMAC-mimetic compound, SM-164, requires activation of caspases.
    Yang J; McEachern D; Li W; Davis MA; Li H; Morgan MA; Bai L; Sebolt JT; Sun H; Lawrence TS; Wang S; Sun Y
    Mol Cancer Ther; 2011 Apr; 10(4):658-69. PubMed ID: 21282353
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.